2021 TDDW Abstract Book

2021 TDDW

Symposium (VIII) INTERVENTIONAL ONCOLOGY IN DIGESTIVE MEDICINE

LEGACY: LOCAL RADIOEMBOLIZATION USING GLASS MICROSPHERES FOR THE ASSESSMENT OF TUMOUR CONTROL WITH Y-90 Vivian Bishay Department of Radiology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA The LEGACY Study is the first multicenter study to report a high median perfused volume absorbed dose of 410 Gy with TheraSphere, which resulted in an 88% best response (84% complete response), durable tumor control and high overall survival rate in patients with early and advanced HCC.

At three years the overall survival rate for patients was 93% in patients with transplant or resection following TheraSphere and 84% for patients who had TheraSphere as a primary treatment, with 96.8% of patients responding to treatment following one TheraSphere treatment and 100% response with two treatments.

Turn static files into dynamic content formats.

Create a flipbook

Articles inside

2021 TDDW Abstract Book

Articles inside

V) Cirrhosis & HCC

IV) Pancreas / Biliary

II) LGI

I) HCV

XV) Interventional Oncology in HCC

XVI) Small Bowel Lymphoma

XIV) HBV/HCC Symposiums

Pandemic

XII) Organ-Gut Axis: Innovation to Practice

X) Strategies to Improve Outcome for Gastric Cancer in Taiwan

IX) New Diagnostic Modalities in Digestive Diseases

National Scale

VIII) Interventional Oncology in Digestive Medicine

VI) First Line Combination Therapy or Sequential Therapy for HCC

V) Updates in the Treatment of Functional GI Disorder

IV) NASH Symposium

Pancreatic Cancer

I) Third Space Endoscopy – 2021 Update

Chicago 4.0

V) Update Surgical Strategy toward Pancreatic Cancer in Japan

IV) From Innovation to Clinical Practice: Co-creation Model and Case Study

Metastatic Pancreatic Cancer

I) Colon Cancer: The Roles of Gut Microbiota

III) Emerging Trends of Inflammatory Bowel Disease in Asia